

SESSION 2

Part 1: Scientific Fundamentals of PPI Studies

Martin Ho

Associate Director for Quantitative Innovation
Office of Surveillance and Biometrics
FDA Center for Devices and Radiological Health

Juan Marcos Gonzalez

Assistant Professor
Department of Population Health Sciences
Duke Clinical Research Institute


FDA-CERSI Patient Preference Workshop
December 7-8, 2017



Objectives

1. Science: Introduction to science of PPI
2. Scope: Where science and regulatory-needs meet
3. Context: Explain why study quality matters
4. Approach: How CERSI and FDA can collaborate to advance science of PPI

PPI: Where Regulatory Needs Meet Science



Regulatory Considerations of PPI Studies



Context specific to individual regulatory decisions

1. Chosen method informs benefit-risk assessment.
2. Patients can understand & answer the questions.
3. Descriptions of treatment options (benefits & risks etc.) are accurate with minimum cognitive bias.
4. Study sample is sufficiently large and diverse that reflects the population of interest.



Some Useful Resources

- Your FDA review divisions (come early and often!)
- CBER-CDRH Patient Preference Information Guidance (<https://goo.gl/N1BDTw>)
- Patient Reported Outcome Guidance's Qualitative Section (<https://goo.gl/UpJ6EV>)
- Science of Patient Input at MDIC (<http://mdic.org/spi/>)
 - Framework and Catalog (<https://goo.gl/SqrZLR>)
 - NEW** **Qualitative Steps** (<https://goo.gl/owAABB>)
- PFDD Patient Experience Data Workshop, Dec. 18 (<https://goo.gl/ZMX6Lr>)